IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference

Core Insights - IDEAYA Biosciences, Inc. is participating in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, where CEO Yujiro S. Hata will present [1] - The company focuses on precision medicine in oncology, aiming to develop targeted therapies that are tailored to the genetic drivers of cancer [2] Company Overview - IDEAYA is dedicated to the discovery, development, and commercialization of transformative cancer therapies, integrating small-molecule drug discovery, structural biology, and bioinformatics [2] - The company has a robust pipeline of product candidates, particularly in synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications [2] - The mission of IDEAYA is to create the next generation of precision oncology therapies that are more selective, effective, and personalized, with the goal of improving clinical outcomes for cancer patients [2]